Celularity (NASDAQ:CELU) Shares Up 1.3% on Analyst Upgrade

Celularity, Inc. (NASDAQ:CELU) traded up 1.3% during mid-day trading on Monday after Wall Street Zen upgraded the stock from a sell rating to a hold rating. The company traded as high as $4.00 and last traded at $3.84. 36,127 shares changed hands during trading, a decline of 55% from the average session volume of 80,518 shares. The stock had previously closed at $3.79.

Separately, WBB Securities initiated coverage on Celularity in a research note on Monday, August 18th. They set a “moderate buy” rating and a $6.00 price target for the company.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CELU. Acadian Asset Management LLC purchased a new stake in shares of Celularity during the 1st quarter worth approximately $34,000. XTX Topco Ltd grew its holdings in Celularity by 106.4% during the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after purchasing an additional 11,057 shares during the period. Bank of America Corp DE increased its position in Celularity by 1,538.1% in the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after buying an additional 35,023 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Celularity in the fourth quarter valued at $93,000. Finally, Valmark Advisers Inc. purchased a new position in shares of Celularity during the 2nd quarter valued at $98,000. 19.02% of the stock is owned by institutional investors.

Celularity Price Performance

The company has a current ratio of 0.38, a quick ratio of 0.28 and a debt-to-equity ratio of 4.07. The stock has a market cap of $91.97 million, a PE ratio of -1.45 and a beta of 0.79. The business has a 50-day moving average price of $2.75 and a 200 day moving average price of $2.10.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.